OA01.06 Randomised Phase 2 Study of Nivolumab (N) Versus Nivolumab and Ipilimumab (NI) Combination in EGFR Mutant NSCLCG. Lai,J. Alvarez,J.C. Yeo,N.L. Sim,A. Tan,S. Zhou,L. Suteja,T.W. Lim,N. Rohatgi,J. Yeong,A. Takano,K.H.T. Lim,A. Gogna,C.W. Too,K.D. Zhuang,A. Jain,W. Tan,R. Kanesvaran,Q.S. Ng,M. Ang,T. Rajasekaran,L. Wang,C.K. Toh,W. Lim,W.L. Tam,F. Ginhoux,S.H. Tan, A. Skanderup,D. Tan,E. TanJournal of Thoracic Oncology(2021)引用 6|浏览10暂无评分AI 理解论文溯源树样例生成溯源树,研究论文发展脉络Chat Paper正在生成论文摘要